Estée Lauder's family injects $200M into Alzheimer’s Drug Discovery Foundation

Amber Tong

Alzheimer’s Drug Discovery Foundation, a philanthropic venture group that’s funded hundreds of research projects for drugs, diagnostics and biomarkers, is getting a $200 million boost …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Estée Lauder's family injects $200M into Alzheimer’s Drug Discovery Foundation

Amber Tong

Sign up to read this article for free.

GSK leaves biotech trade group BIO

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Eisai slashes Leqembi sales forecast by almost $100M

Amgen and AstraZeneca share positive results in chronic rhinosinusitis

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Es­tée Laud­er's fam­i­ly in­jects $200M in­to Alzheimer’s Drug Dis­cov­ery Foun­da­tion

Amber Tong

Sign up to read this article for free.

GSK leaves biotech trade group BIO

Biotech in­dus­try wor­ries over po­ten­tial for RFK Jr. al­ly as FDA pick

Ei­sai slash­es Leqem­bi sales fore­cast by al­most $100M

Am­gen and As­traZeneca share pos­i­tive re­sults in chron­ic rhi­nos­i­nusi­tis

Benev­o­len­tAI’s co-founder is back. Here’s how he plans a turn­around at the AI com­pa­ny dur­ing a ‘piv­otal time’

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Estée Lauder's family injects $200M into Alzheimer’s Drug Discovery Foundation

Biotech industry worries over potential for RFK Jr. ally as FDA pick

Eisai slashes Leqembi sales forecast by almost $100M

Amgen and AstraZeneca share positive results in chronic rhinosinusitis

BenevolentAI’s co-founder is back. Here’s how he plans a turnaround at the AI company during a ‘pivotal time’

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks